National Bank of Canada
CRDF icon

National Bank of Canada’s Cardiff Oncology CRDF Stock Holding History

National Bank of Canada’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,087
Closed -$430K – 2930
2025
Q3 		$430K Buy
+2,087
New +$5.77K ﹤0.01% 1379

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

National Bank of Canada's CRDF Position: Q4 2025 in Review

National Bank of Canada sold out of Cardiff Oncology (CRDF) in Q4 2025, closing a stake of 208,700 shares — an estimated $430K sold.

National Bank of Canada first reported a position in CRDF in Q2 2025 and held it in 2 quarters. The position peaked at $430K in Q3 2025. 110 funds tracked by Wall St. Rank hold CRDF as of Q4 2025.

  • National Bank of Canada reported no remaining Cardiff Oncology position as of Q4 2025 after selling out during the quarter.
  • National Bank of Canada sold 208,700 Cardiff Oncology shares in Q4 2025, an estimated $430K.
  • National Bank of Canada first reported a position in Cardiff Oncology in Q2 2025 and held it in 2 quarters.
  • National Bank of Canada's Cardiff Oncology position peaked at $430K in Q3 2025.
  • 110 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2025.

Based on National Bank of Canada's 13F filing for Q4 2025, filed 17 Feb 2026.